| |
CAR-T therapies have transformed treatment for certain hematological malignancies, but their use is limited. Ongoing research seeks to improve safety, efficacy, and lower costs, expanding their application. To learn more, download our white paper. 
|
|
Today’s Big NewsSep 20, 2024 |
|
Understanding the metabolic pathways of NCEs in different species increases the likelihood that the most applicable species are selected for preclinical toxicology studies. Read More >> 
|
|
| By James Waldron Novo Nordisk’s $1 billion bet that it had found a cannabinoid CB1 receptor blocker that could reduce weight while avoiding the psychiatric effects that capsized Sanofi’s Acomplia faces new questions after the company revealed mid-stage headline results. |
|
|
|
By Nick Paul Taylor Sanofi has shared data from the phase 3 HERCULES trial that could rescue its multiple sclerosis (MS) drug candidate tolebrutinib, linking the BTK inhibitor to a 31% delay in time to onset of confirmed disability progression. The drugmaker plans to seek approval this year. |
By Gabrielle Masson Aligos Therapeutics is heralding a midstage win in metabolic-dysfunction associated steatohepatitis after three different doses of its drug candidate significantly slashed liver fat at 12 weeks. Despite the company's enthusiasm, the results failed to impress investors. |
Sponsored by Avacare Clinical Research Network With intricate protocols and shifting regulatory demands, it’s more difficult than ever to find and keep participants, as well as gather reliable data. |
|
Create an optimal path to the clinic that best suits your molecule and critical milestones. We now offer a full suite of integrated drug substance/drug product DNA-to-IND programs to accelerate any molecule type to the clinic. Download our white papers to learn more about our tailored CMC strategies. 
|
|
By Zoey Becker Edgewise tested its drug, dubbed EDG-7500, separately in healthy subjects and in patients with obstructive HCM. |
By Nick Paul Taylor Slow enrollment in a key clinical trial has driven Genfit to rework the protocol to try to keep the study on track. The biotech said the changes reflect the comorbidities of people with acute on-chronic liver failure (ACLF) and the logistics of caring for the patients. |
By Darren Incorvaia Two new papers show how TRIM21 techniques can remove tau tangles inside of mouse neurons and improve mobility in a mouse model of Alzheimer’s disease. |
By Darren Incorvaia,Zoey Becker Warren Biddle hit the exit from his role as SVP, global head of commercial at Gilead’s CAR-T unit Kite Pharma to take on the CEO gig at fellow CAR-T maker Kyverna, effective immediately. |
By Angus Liu Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck and Eisai's Keytruda-Lenvima combo delivered a win in liver cancer. An FDA document details shortfalls at a Granules plant in India. Plus more. |
By Angus Liu Gilead Sciences’ Kite Pharma will sell its stake in China’s Fosun Kite Biotechnology nearly eight years after forming the cell therapy-focused joint venture with Fosun Pharma. |
By Dave Muoio Pieces Technologies agreed to more clearly disclose how it is describing its tools’ performance and to provide more explicit disclosures to its hospital customers covering how the products are to be used and could potentially lead to patient harm. |
Fierce podcasts Don’t miss an episode |
| In this week's episode of "The Top Line," we’re recapping and discussing the major trends from Digitial Pharma East. |
|
|---|
|
|
Whitepaper Unique Solutions for Drug Discovery and Development Sponsored by: Cell Signaling Technology |
Whitepaper When the fate of your company hangs in the balance, you need expert guidance to navigate the complexities of biotechnology development and to make informed decisions. Sponsored by: WCG |
Whitepaper Power non-invasive, self-sampling solutions using the Colli-Pee™️ first-void urine collection device. Learn more. Sponsored by: DNA Genotek |
Whitepaper Facing roadblocks in drug development? Uncover how phase-appropriate technology transfers can help you navigate challenges and speed up your journey to market. Sponsored by: Veranova |
Whitepaper We interviewed dozens of biopharma leaders on the critical success factors for building a Best Practice commercial organization. This report shares what we learned. Sponsored by: Blue Matter Consulting |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
